Drugs / BTI320
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03655535 | Sep 2018 → Aug 2019 | type 2 diabetes mellitus | Boston Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02358668 | Mar 2015 → Feb 2016 | prediabetes syndrome | Chinese University of Hong Kong | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTI320 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03655535 ↗ |
| Action | Inhibit | “BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut.” NCT02358668 ↗ |
| Route | Oral | “three times daily, oral for 16 weeks” NCT02358668 ↗ |